170results about "Antipyretic" patented technology

Low viscosity biodegradable polymer solutions of a liquid biodegradable polymer and biocompatible solvent and methods of using the compositions to form a liquid polymer implant are provided.

The present invention is to obtain novel anti-inflammatory agents having decreased antibacterial activity and increased anti-inflammatory action, and is psedoerythromycin derivatives represented by the following general formula [I],wherein R1 and R2 are same or different and each represents H, alkyl, alkynyl, acyl or sulfonyl, in which these groups may optionally have substituents, and Me indicates methyl.

The conjugate compositions and methods are useful to elicit/augment an immune response to a tumor or microbial infection or to reduce the severity of autoimmunity, chronic inflammation, allergy, asthma, periodontal disease, and transplant rejection.

A process is provided for preparing spiro-hydantoin compounds of the formula II

wherein Z is N or CR_4b; K and L are independently O or S; Ar is an optionally substituted aryl or heteroaryl; A₂ is a linker, G′ is a linker; Q is a linker; and R₂, R_4a, R_4c, and R_h are defined in the specification. The process optionally includes the enantiomeric separation of intermediates to allow preparation of enantiomers of the spiro-hydantoin compounds of formula II. Substituted spiro-hydantoin compounds may be prepared from the spiro-hydantoin compounds of formula II. The spiro-hydantoin compound of formula II and the substituted spiro-hydantoin compounds are useful in the treatment of immune or inflammatory diseases. Also, provided are products made by the instant inventive process and crystalline forms (prepared by any process) of the substituted spiro-hydantoin compound, 5-[(5S, 9R)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-thiophene-3-carboxylic acid, including solvates and salts thereof, as well as methods of use thereof. Crystalline forms of certain intermediates are provided.

The present invention refers to the use of phthalimide and/or sulphonamide derivatives with nitric oxide donor properties, which have important activities in increasing the gamma-globin gene expression and anti-inflammatory and analgesic activities, effective in the treatment of hematologic diseases which require reducing the TNF-α levels and an exogenous source of nitric oxide. More particularly, the present invention describes the use of such phthalimide and/or sulphonamide derivatives for the treatment of sickle-cell disease. The invention also has as a novel characteristic the disclosure of new functionalized phthalimide derivatives designed from the prototypes thalidomide and hydroxyurea, and designed rationally through the strategy of molecular hybridization for the treatment of said diseases. The invention still discloses a new method for obtaining a specific sulphonamide derivative which can be used in the preparation of a drug for the treatment of diseases which require reducing the levels of the TNF-α factor and an exogenous source of nitric oxide.

Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/AL20R2 and IL22R1/AL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treat-ing various diseases and disorders, including autoimmune or inflammatory diseases or disorders.

The water solution of bee glue includes the following steps: mixing bee glue and 95 % concentration alcohol solution via stirring, adding to water at 50-100 deg.c to obtain mixed water solution of bee glue and alcohol with alcohol content of 20-60 %, cooling to room temperature, letting stand and filtering; recovering alcohol and filtering to obtain filtrate; repeated alcohol dissolving and filtering of the filter residue and deposited matter to obtain filtrate; merging filtrate, concentration at 80 deg.c or adding water to density of 1.01-1.04, cooling, filtering to obtain the water solution of bee glue. The alcohol dissolving and water extracting process is simple, and the water solution of bee glue has high flavone content, no organic solvent and additive, low preparation cost and good biological effect. The water solution of bee glue may be used in preparing products for lowering blood sugar, lowering blood fat, resisting inflammation and regulating immunity.

Fibrin-binding peptides having high binding affinity and excellent physical characteristics compared to previously known fibrin-binding peptides are provided. These fibrin-binding peptides may be conjugated to a detectable label or a therapeutic agent and used to detect and facilitate treatment of pathological conditions associated with the presence of fibrin such as thrombic, angiogenic and neoplastic conditions. These peptides may be used in imaging processes such as MRI, ultrasound and nuclear medicine imaging (e.g. PET, scintigraphic imaging., etc.). The peptides may also be used therapeutically. The present invention also provides processes and methods for making and using such peptides and conjugates thereof.

Described herein are substituted 2-(azetidin-2-on-1-yl)alkanoic acids, alkanedioic acids and 2-hydroxyalkyl alkanoic acids, and 2-acyl alkanoic acids, and derivatives thereof, that are capable of modulating activity at the cannabinoid-1 (CB1) and/or cannabinoid-2 (CB2) receptor. Also described herein are methods for treating mammals in need of relief from disease states associated with and responsive to modulation of the CB1 and/or CB2 receptor activity.

The present invention is to provide an imidazolidinedione derivative and oxazolidinedione derivative represented by the following general Formula (I) having the chymase and/or tryptase inhibition activity [wherein R<1 >and R<2 >are the same or different, and denote a lower alkyl group or a phenyl group, or R<1 >and R<2 >are taken together to form a ring, R<3 >denotes an optionally substituted naphthyl group or heterocyclic group, A denotes oxygen or NR<4 >(R<4 >is hydrogen or optionally substituted lower alkyl group), or NB<2>R<5 >(R<5 >is aryl group, and B<2 >is carbonyl group or sulfonyl group), and B<1 >denotes a carbonyl group or a sulfonyl group], or a pharmaceutically acceptable salt thereof.

The invention described herein relates to new combretastatin derivatives obtained by total synthesis and having the following general formula:

in which the groups are as defined in the description here below. Said compounds, though chemically related to the structure of cis/trans-combretastatin, do not always bind tubulin, but nevertheless exhibit cytotoxic activity of interest in the oncological field as anticancer and/or antiangiogenic agents.

The invention discloses a traditional Chinese medicine combination used for treating rheumatic heart disease and pertains to the Chinese medicine field. The Chinese medicine preparation takes the following ingredients as the active ingredients: root of rehmannia, radix codonopsis pilosulae, red sage root, fourstamen stephania root, medical glue, radices polygonati officinalis, lilyturf root, cassia twig, fructus schizandrae, liquorice and wu chia pee. The traditional Chinese medicine combination used for treating rheumatic heart disease have the effects of benefiting vital energy, enriching the blood, enheartening the heart-yang, nourishing the heart, benefiting the pulse, promoting blood circulation by removing blood stasis and repairing an impaired heart valve.

The invention pertains to an aqueous composition containing lactoferrin, 35-70 wt % carbohydrate and/or polyol stabilizers, based on the total weight of the aqueous composition, said composition exhibiting a pH higher than 2, lower than 5. At these 5 conditions, the aqueous composition and lactoferrin contained therein may be subjected to a heat treatment without significantly affecting the physiological activity of the lactoferrin. The invention thus particularly pertains to the above aqueous composition, being heat-treated, thus containing heat-stabilized lactoferrin.

The invention belongs to the field of skin-care products, and discloses an anti-allergy skin-soothing essence and a preparation method thereof. The anti-allergy skin-soothing essence is prepared fromthe following components: deionized water, a pot marigold extract, an aloe extract, a pot marigold/Chinese mugwort fermentation extract, corn gluten, hydroxyethyl cellulose, hyaluronic acid, glycerine, butanediol, and beeswax. The anti-allergy skin-soothing essence disclosed by the invention adopts scientific and rational raw material proportion, and fully utilizes soothing and anti-allergic effects of the pot marigold extract, the aloe extract and the pot marigold/Chinese mugwort fermentation extract, as well as skin elasticity increasing effect of the corn gluten, so that the components exist side by side and play a part together so as to endow the essence with the effects of effectively improving common problems of allergic skin and removing accumulated turbid matters in the skin as well as harmful substances caused by pollution, thereby achieving the functions of nourishing the skin, resisting allergy, diminishing inflammation, tightening the skin, whitening and moisturizing; and thus, the anti-allergy skin-soothing essence is capable of cleaning, nourishing and protecting the skin, as well as effectively soothing the skin, resisting allergy and preventing skin split caused bydryness.

The invention belongs to the field of medicine and personal care, and particularly relates to propolis-aloe bacteriostatic gel and a preparation method thereof. The propolis-aloe bacteriostatic gel isprepared from the following raw materials in percentage by mass: 8-12% of golden cypress, 8-10% of fructus cnidii, 6-11% of stemona, 9-12% of fructus kochiae, 7-9% of divaricate saposhnikovia roots,4-8% of seaweeds, 3-6% of aloes, 0.5-0.8% of propolis, 1-1.4% of chlorhexidine acetate, 0.8-1.2% of carbomer 940, 0.08-0.11% of methylparaben, 0.09-0.12% of triethanolamine, 0.9-2.1% of ethanol and 36-40% of purified water. The propolis-aloe bacteriostatic gel is propolis-aloe gel prepared through the compound compatibility of the propolis and the aloes, through the synergistic effect of the propolis and the aloes, the effects of inhibiting the growth of bacteria, promoting wound healing, diminishing inflammation, realizing sterilization, realizing moistening and nourishing, replenishing water, removing acne, removing eczema and realizing spot-fading can be effectively achieved, and especially, the bacteriostatic effect on escherichia coli, staphylococcus aureus, hemolytic streptococcus and the like is achieved.

The invention discloses an easing acesodyne plaster which contains the following components: 10-30 parts of glycerinum, 2-8 parts of seaweed gel, 0.5-1 part of oleum gaultheriae, 10-20 parts of mint leaf oil, 5-7 parts of citronella oil, 4-8 parts of eucalyptus globulus oil, 5-20 parts of cortex eucommiae, 5-10 parts of rose oil, 3-10 parts of sandalwood oil, 4-10 parts of guard reversal extract, 3-10 parts of eucalyptus extract, 2-8 parts of vernonia gratiosa extract, 0.5-1.5 parts of ginger extract, 1-20 parts of water, 2-5 parts of system stabilizer, 0.05-3 parts of thickening agent and 0.1-5 part of alcohol. The formula adopted by the invention has the effects of clearing heat, relieving pain, promoting circulation and removing stasis; the specially treated eucommia staminate flowers are selected for mutually complementing and reinforcing the other components in the drug; the easing acesodyne plaster has the effects of fast effectiveness, curative effect and difficulty in recurring in treating persistent pain, especially, arthritis pain, traumatic injury and haemorrhoids.